Evaluation of spinning disk reactor technology for the manufacture of pharmaceuticals

A continuously operating spinning disk reactor (SDR) displayed distinct adv antages over batch processing techniques when several commercially relevant processes for the manufacture of pharmaceuticals as test reactions were in vestigated. It proved to be a useful tool for revealing intrinsically fast kinetics as well as for optimizing processes with such kinetics. Very encou raging results were achieved for a phase-transfer-catalyzed (ptc) Darzen's reaction to prepare a drug intermediate and the recrystallization of an act ive pharmaceutical ingredient (API). In comparison to presently used batch processes, the ptc reaction resulted in a reaction with 99.9% reduced react ion time, 99% reduced inventory, and 93% reduced impurity level. The recrys tallization yielded particles with a tight particle size distribution and a mean size of around 3 mu m. Reactor modeling was in good agreement with th e experimental results and highlighted the advantages of the process-intens ified equipment,with a production capacity of around 8 tonnes/year.